Core Viewpoint - CareDx is focusing on advancing AI-enabled relapse monitoring for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) post-cell therapy, positioning itself as a leader in precision medicine for cell therapy [1]. Group 1: Company Overview - CareDx is conducting an investor webinar to discuss its initiatives and advancements in precision medicine [1]. - The company aims to enhance its competitive position and explore potential growth opportunities within the industry [2]. Group 2: Future Outlook - CareDx's future business plans include the development of testing services and digital solutions aimed at increasing revenue and commercial success [2]. - The company is engaged in clinical trial collaborations and registry studies to support its growth and market opportunities [2].